HK Stock Market Move | ZAI LAB (09688) Rises Over 10% Again; Q3 Product Revenue US$107.6 Million; Zoci Global Clinical Development Achieves New Progress

ZAI LAB (09688) rose over 10% again. As of press time, it was up 10.02% at HK$20.2, with a turnover of HK$24.0396 million. On the news front, ZAI LAB recently disclosed its third-quarter 2026 results. During the reporting period, the company's total revenue was US$108.2 million, of which net product revenue was US$107.6 million, up 2% quarter-on-quarter, mainly driven by increased market coverage and penetration of Xacduro and the launch of xanomeline trospium chloride. In terms of innovative drug R&D, zocilurtatug pelitecan (zoci), a DLL3-targeting ADC independently developed by ZAI LAB, is the company's core product with the most advanced R&D progress. Dr. Ying Du, Founder, Chairwoman and Chief Executive Officer of ZAI LAB, said that the strong data on first-line combination therapy with zoci presented at the ESMO Congress strengthened the company's confidence that it has the potential to become the preferred backbone ADC for small cell lung cancer. 2027 will be a pivotal year, and the company expects to submit the first Biologics License Application (BLA) for zoci in the United States.